MedTrace Logo

Safety Study of Increasing Doses of Combretasatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Hepatic Tumor Burden

NCT00960557 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2011-08-23

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and tolerability of OXi4503 in subjects with relapsed or refractory carcinomas with hepatic tumor burden.

Conditions

  • Neoplasm Metastasis

Interventions

DRUG

Combretastatin A1 Diphosphate (OXi4503)

OXi4503 administered IV on Days 1, 8, and 15 of each 28-day cycle.

Sponsors & Collaborators

  • Mateon Therapeutics

    lead INDUSTRY

Principal Investigators

  • Michael Brown, MD · Royal Adelaide Hospital

  • Jason Lickliter, MD · Monash Medical Centre

  • Paul Mainwaring, MD · Mater Adult Hospital

  • Michael Millward, MD · Sir Charles Gairdner Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2010-10-31
Completion
2010-10-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00960557 on ClinicalTrials.gov